Answers are grounded in this paper and cite their sources.
Traumatic brain injury (TBI) is a significant concern, with millions sustaining a TBI each year. The vast majority are categorized as mild, in which diffuse pathologies are the hallmark and multiple cell types are affected, including astrocytes. Buprenorphine (bup), a semi-synthetic opioid, is a common human and veterinary analgesic. Previous studies from our group showed that a single dose of slow-release bup administered acutely following TBI alters astrocyte morphology at 1 day and 4 weeks post-injury in a region-specific manner. The current study expands on these findings by examining how four major astrocyte-associated proteins, GFAP, SWELL1/LRRC8A, TRPM4, and AQP4, are affected by such a dose of bup. Adult male rats received either a sham or TBI via a central fluid percussion injury model, followed by saline or bup 15 min following injury. Protein quantification at 1 day and 4 weeks post-injury revealed region- and time-dependent effects of acute bup administration. At 4 weeks following TBI, bup treatment was associated with reduced cortical SWELL1 and TRPM4, and reduced hippocampal and thalamic AQP4 expression. Collectively, these findings suggest that a single post-injury dose of bup can alter the regional expression of major astrocyte-associated proteins beyond the acute phase following diffuse TBI.
No takes yet. Share an insight, caveat, or question.
Lilova et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: